Truist analyst David MacDonald lowered the firm’s price target on Quest Diagnostics to $145 from $155 and keeps a Hold rating on the shares. The company’s Q3 results reflected “solid” base business trends, but while the payer commentary was upbeat and cost initiatives continue to progress, labor remains a challenge and margin expectations were “slightly tweaked”, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics announces collaboration with Diadem SpA
- Quest Diagnostics price target lowered to $130 from $142 at Citi
- Quest Diagnostics narrows FY23 adjusted EPS view to $8.65-$8.75 from $8.50-$8.90
- Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
- Quest Diagnostics reports Q3 adjusted EPS $2.22, consensus $2.19